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Abstract
Background: Persons with spinal cord injury (SCI) often have low levels of physical activity, which predispose to
increased adiposity and decreased high density lipoprotein cholesterol (HDL-C) concentrations, and, generally,
normal low density lipoprotein cholesterol (LDL-C) concentrations. In spite of the mixed lipoprotein profile, the SCI
population has been reported to have an elevated risk of cardiovascular-related morbidity and mortality. Nuclear
magnetic resonance spectroscopy may permit a more precise quantification of lipoprotein particle (P) species,
enabling a more accurate inference of risk for cardiovascular disease (CVD) in the SCI population.
Methods: Fasting blood samples were obtained on 83 persons with chronic SCI and 62 able-bodied (AB) subjects.
Fasting plasma insulin (FPI), triglycerides (TG), and P number and size of VLDL (very low density lipoprotein), LDL,
and HDL subclasses were determined. AB and SCI subjects were stratified based on HDL-C (i.e., Low <40 and
Normal ≥40 mg/dl): AB-Normal (n = 48), AB-Low (n = 14), SCI-Normal (n = 49), and SCI-Low (n = 34). Factorial
analyses of variance were performed to identify group differences in lipoprotein measurements. Pearson
correlations were performed between the number of P by lipoprotein subclass, size, FPI, and TG.
Results: The SCI-Normal group was not significantly different from the AB-Normal group for body composition,
FPI, TG or LP-IR and had negligible differences in the lipoprotein P profile, except for fewer number and smaller
size of HDL-P. The SCI-Low group had a similar lipoprotein profile to that of the AB-Low group, but with a lipid
P composition associated with a heightened atherogenic risk and greater tendency toward insulin resistance by
the Lipoprotein-Insulin Resistance (LP-IR) score. In the SCI-Low group, the decreased number and reduced size of
lipoprotein P were more prevalent and may be associated with increased waist circumference (i.e., abdominal
adiposity), relatively elevated TG values (compared to the other subgroups), and an underlying subclinical state of
insulin resistance.
Conclusions: Prolonged sitting and restricted physical activity in individuals with SCI had the most profound effect
on the HDL-C and its lipoprotein P subclasses, but not on LDL-C, however its P subclasses were also unfavorably
affected but not to the same degree. The quantification of lipoprotein P characteristics may be a potent tool for
the determination of risk for CVD in persons with SCI.
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Background
The lipoprotein profile is a common clinical measure-
ment used to stratify risk for coronary artery disease
(CAD). Outcomes from decades of population-based
epidemiological research have provided optimal ranges
for high- and low-density lipoprotein cholesterol con-
centrations (HDL-C and LDL-C, respectively), that when
coupled with other health, behavior and lifestyle assess-
ments serve to provide clinicians with an estimate of the
potential burden of subclinical vascular atherogenesis.
Nuclear magnetic resonance (NMR) technology has ad-
vanced the diagnostic precision for lipoprotein choles-
terol measurement by providing the concentration of the
number of HDL, LDL, and very low density lipoproteins
(VLDL) particles (HDL-P, LDL-P and VLDL-P, respect-
ively) for sub-particle classifications (i.e., particle sizes
ranging from small to large) [1] and, thus, provide the
ability to further differentiate the proportion of potentially
atherogenic to potentially anti-atherogenic lipid particles
in the circulation. The insight gained from combining
lipoprotein cholesterol concentration with that of the lipo-
protein particle number is anticipated to permit a more
accurate estimate of risk for vascular events [2–4]. Such
an approach should serve to more appropriately guide
clinical intervention with pharmaceutical and/or lifestyle
modification (i.e., physical activity, diet, smoking, etc.) to
lower cardiovascular disease (CVD) risk.
Reduced physical activity has gained increased atten-
tion as a strong associate of obesity, insulin resistance,
and dyslipidemia, and these disorders are being observed
earlier in the lifespan and at a higher incidence in per-
sons with sedentary lifestyles than in more active indi-
viduals [5, 6]. Engaging in regular physical activity has
been shown to decrease the risk for CVD-related mor-
tality by as much as 40 % [7]. According to a report by
the National Institute of Disability and Rehabilitation
Research on the total non-institutionalized population in
the United States, 13.6 % (31.3 million) of respondents
report some activity limitation due to chronic health
conditions, 3.8 % (8.8 million) are not able to perform
any major activity, and 5.9 % (13.6 million) are limited in
the amount or kind of major activity [8]. Although con-
sidered a modifiable risk factor for CAD in the general
population, the magnitude of physical activity required
to achieve cardiorespiratory fitness and a clinically
meaningful change in biomarkers of CAD is not attain-
able in those with a severe physical disability, such as
with spinal cord injury (SCI). There are an estimated
238,000-332,000 persons with SCI living in the United
States, with about 12,000 new cases presenting annually
[9]. Advances in the acute and chronic medical manage-
ment of persons with SCI have resulted in increased sur-
vival rates, leading to lifespans approximating that of the
general population. In spite of improved survival outcomes,
persons with SCI are faced with significant morbidity and
medical challenges due, in large part, to the deleterious
metabolic consequences of physical inactivity. After SCI, a
significant adverse shift occurs in body composition and
metabolism; there is an initial rapid, and then more insidi-
ous and progressive, lean tissue atrophy below the neuro-
logical level of injury [10–13], an increased adiposity [14]
with an associated heightened prevalence of insulin resist-
ance and disorders of carbohydrate metabolism (e.g., im-
paired glucose tolerance, and diabetes mellitus) than that
reported in the general population [12, 15–18]. During the
chronic phase of SCI, a characteristic dyslipidemia in the
SCI population is well appreciated to occur, with mean
serum HDL-C concentrations <40 mg/dl [19], and, occa-
sionally, elevated mean serum triglyceride concentrations
[20]. It should not be of surprise that CVD-related morbid-
ity in persons with SCI occurs earlier in life, at a greater
prevalence than that of the general population, and is the
primary cause of death after the first year of injury [21–23].
Population-based studies are difficult to perform be-
cause of the low incidence rates for SCI. Evidence-
based treatment targets used in the general population
may be inappropriate to medically manage a chronically
immobilized population. Additional relevant informa-
tion is needed to generate a better understanding of
CAD burden in individuals with SCI in order not to
underestimate risk. Effective treatment to reduce risk
of CAD is dependent on early and accurate diagnosis;
NMR spectroscopy offers potent clinical insight to as-
sess atherogenic risk. With consideration for the ele-
vated risk of CVD-related morbidity in the SCI
population that is imparted by prolonged sitting times
and restricted physical activity, the use of findings from
NMR methodology may serve to identify those with
SCI who have an adverse lipoprotein profile by lipid
particle size and number, and the presumed association
with insulin resistance, and also provide security of
knowing that others with SCI are at lower risk. This
study will report values and associations among the
lipoprotein subclasses for particle size and number in
persons with SCI for HDL-C at or above and below
40 mg/dl, the threshold level that is appreciated to be
an independent risk factor for CAD. Knowledge of
these interrelationships and the influence of inactivity
on lipid particle size and risk for CAD may serve to
further alert the medical community to provide guid-
ance and more appropriate treatment to those with SCI
who are identified to be at greatest vascular peril.
Methods
Subjects
Eighty-three individuals with non-ambulatory chronic SCI
(>6 months post-SCI) and 62 able-bodied individuals
were recruited for participation from the SCI Service,
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outpatient clinics and hospital staff of the James J. Pe-
ters Veterans Affairs Medical Center, Bronx, NY, and
the Kessler Institute for Rehabilitation, West Orange,
NJ. Men and women between the ages 20 and 65 were
considered for study eligibility as a control or SCI sub-
ject if they were free of acute medical illness (i.e., not
receiving treatment for an active medical condition),
without known diagnosed chronic illness (i.e., heart
disease, pulmonary disease, diabetes mellitus), and had
the capacity to provide informed consent. Women
were excluded from consideration if they were preg-
nant. No subjects were taking medications with known
effects on any of the study-related outcome measure-
ments; this list may include, but was not limited to all
classes of hypolipidemic agents, insulin/insulin-sensi-
tizing agents, or hormone-replacement therapies. No
individuals who participated in this study were en-
gaged in competitive athletics/training at the time of
their enrollment. The study was approved by the Insti-
tutional Review Boards of the two study sites. Written
informed consent was obtained from each subject
prior to study participation.
Data collection
Subject demographic, medical history, anthropometrics
and venous blood samples were obtained during a single
study visit. All participants were required to complete an
overnight fast prior to arriving at the testing center be-
tween 8 and 11 a.m. for study evaluation, which included
venous blood collection for determination of the lipid
profile, lipid particle number and size, glucose and
plasma insulin concentrations. Analysis for the serum
lipid profile [total cholesterol, triglycerides, HDL-C and
estimated LDL-C] was determined in the General Chem-
istry Laboratory of the host institution using an ADVIA
1650 automatic chemistry analyzer following standard
procedures recommended by the manufacturer (Bayer
Diagnostics, Newbury, UK). The HDL-P, LDL-P and
VLDL-P number and size were determined using auto-
mated NMR Lipoprofile 3 (LP3) lipoprotein particle ana-
lysis, by previously described methods (LipoScience,
Inc., Raleigh, NC) [24]. From the LP3 technique, the fol-
lowing lipid particle number measurements were deter-
mined for total VLDL (VLDL-P), total HDL (HDL-P),
total LDL (LDL-P), and for their respective Large and
Small subparticle sizes. A proprietary algorithm was
used to create the Lipoprotein Insulin Resistance (LP-IR)
score (LipoScience, Inc., Raleigh, NC). The LP-IR score,
which is a composite index based upon a proprietary al-
gorithm (Liposcience, Inc., Raleigh, NC) derived from
the number of Large VLDL, Small LDL, Large HDL and
the size of the VLDL, LDL and HDL, ranges from 0
(most insulin sensitive) to 100 (most insulin resistant),
and this index has been suggested to possess a stronger
association to insulin resistance than any independent
parameter alone [25, 26]. Blood samples for fasting
plasma insulin (FPI) were batch processed in duplicate
by radioimmunoassay using techniques previously devel-
oped by our laboratory [27]. Fasting plasma glucose
(FPG) concentrations were performed on an automated
glucose analyzer (YSI 2300 STAT Plus, YSI Life Sciences,
Yellow Springs, OH).
Statistics
For comparison, the AB and SCI groups were dichoto-
mized by the fasting HDL-C concentrations: <40 mg/dl
or ≥40 mg/dl, forming four subgroups: AB-Normal, AB-
Low, SCI-Normal, and SCI-Low. The following were
compared between groups using factorial analysis of
variance: demographic characteristics; anthropometric
measurements; FPG and FPI; lipoprotein profile (i.e.,
HDL-C, LDL-C, TC, and TG); lipoprotein particle mea-
sures (total particles for each subclass: HDL-P, VLDL-P,
LDL-P; HDL, VLDL; and LDL-P sizes: Large and Small
HDL, Large and Small VLDL, Intermediate LDL, Large
LDL, and Small LDL); and LP-IR; a Bonferoni post-hoc
test was used to further characterize significant group
main effects. The LP-IR was plotted to demonstrate the
respective group means and individual scores (per-
formed with GraphPad Prism version 5.04 for Windows,
GraphPad Software, San Diego, CA, USA). To facilitate
our understanding of the observed lipid particle subclass
sizes, separate Pearson correlations to FPI and TG were
performed within each group using bivariate models.
Pearson Chi-square Tests were performed to determine
if the groups differed in the frequency of categorical out-
come measurements. Statistical analyses were completed
using IBM SPSS Statistics 21 (IBM, Armonk, NY, USA).
An a priori level of significance was set at p ≤ 0.05.
Results
Subject characteristics from each of the 4 study groups
are provided (Table 1). The groups were matched for
age and weight, but trended toward a significant group
difference for height (p = 0.09) and body mass index
(BMI) (p = 0.06). The SCI-Low group had significantly
greater waist circumference (p < 0.05) and waist-to-
height ratio (p < 0.05) compared to the AB-Normal
group. Within the two SCI cohorts, there was a similar
distribution of individuals with paraplegia (i.e., injuries to
the thoracic or lumbar spine regions), complete sensori-
motor injuries (i.e., absence of sensation or motor function
below the neurological level of injury), and the duration of
injury. No significant differences were identified between
groups in the frequency of ethnicity (p = 0.13), gender
(p = 0.21) and smoking status (p = 0.87). There was a
significant group main effect for FPG (p < 0.0001) and a
FPI (p < 0.03). Bonferoni’s post-hoc test revealed that
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the AB-Normal group had elevated higher mean FPG
values compared to the SCI-Normal (p < 0.05) and SCI-
Low (p < 0.05) groups, but the group means for FPG
values were all within the normal range (Table 2).
Lipid concentrations and lipoprotein particle number
and size are provided for each of the 4 study groups
(Table 2). In general, the SCI-Normal and AB-Normal
groups were very similar for lipid concentrations and
lipoprotein particles, but the SCI-Normal group had a
comparatively fewer number and smaller size of HDL-P.
By study design, the SCI-Normal group had a higher
HDL-C compared to the AB-Low group, and this favor-
able improvement was displayed in all other lipid and
lipoprotein particle endpoints. The LDL-C values were
statistically similar, across all 4 study groups with the
values residing in an acceptable clinical range, and, as
such, not requiring lipid-lowering treatment. The SCI-
Low group had a more adverse lipid profile, including
that of triglycerides, and lipoprotein particles compared
to the AB-Normal group (Table 2), and tended to have
fewer HDL-P number and smaller particle sizes of com-
pared to its AB-Low group.
Pearson correlations were performed between the re-
spective number of lipoprotein particles by subclass, size,
FPI (Table 3) and TG (Table 4). Except for the AB-Low
group, FPI was the most consistently correlated (i.e.,
trended toward significance, or was significant) to the
number of Small LDL-P and size of the VLDL particle in
the other study cohorts. The SCI-Low group had a greater
number of significant, or trends toward a significant, cor-
relation between the respective sub-particles and FPI;
these relationships were not unexpected because of the
comparatively larger waist circumference observed in the
SCI-Low group to those in the other groups, and thus the
predisposition to insulin resistance. These significant rela-
tionships were supported by the LP-IR, where a significant
group main effect (p < 0.0001) was observed and post-hoc
tests revealed that the SCI-Low group had a significantly
elevated LP-IR compared to the AB-Normal (p < 0.0001)
and SCI-Normal (p < 0.01) groups (Fig. 1). In addition to
FPI, TG concentrations had a demonstrable and deleteri-
ous influence on the lipid distribution (Table 4). Except in
the AB-Low group, TG concentrations were significantly
correlated to the number and size of lipoprotein sub-
classes. Increasing TG concentrations were positively as-
sociated with VLDL size and the number of Total and
Large VLDL-P. TG concentrations were negatively associ-
ated with LDL size, but were positively associated to the
number of Total and Small LDL-P. Increasing TG concen-
trations had no influence on Total HDL-P in all groups,
but resulted in significant negative correlations for Large
HDL-P in the SCI-Normal and SCI-Low groups; statistical
significance was not achieved in the AB groups.
Discussion
Our report is the first to describe the adverse pattern of
lipoprotein particle numbers and size in a highly seden-
tary population—that is, those with SCI who are
Table 1 Characteristics of Study Cohorts by HDL Group
AB-Normal AB-Low SCI-Normal SCI- Low p-value Post-Hoc
n 48 14 49 34 -
Age (yrs) 40.0 (11.4) 39.4 (12.3) 44.2 (11.5) 41.8 (11.4) NS
Height (m) 1.72 (0.09) 1.73 (0.06) 1.75 (0.09) 1.76 (0.09) 0.09
Weight (kg) 82.8 (19.8) 87.3 (16.4) 78.3 (17.3) 87.0 (21.6) NS
BMI (kg/m2) 27.8 (5.5) 29.0 (4.6) 25.4 (4.5) 27.8 (5.3) 0.06
Waist Circumference (cm) 90.0 (13.8) 96.2 (12.9) 96.4 (13.4) 102.2 (16.2) <0.01 1
Waist to Height Ratio 0.53 (0.08) 0.55 (0.07) 0.55 (0.07) 0.58 (0.09) <0.05 1
Paraplegia/Tetraplegia (n) - - 23/26 17/17 -
AIS A/B/C (n) - - 28/7/14 22/4/8 -
DOI (yrs) - - 17.7 (13.4) 14.2 (11.3) NS
Gender M/F (n) 40/9 31/3
Ethnicity (n)
Caucasian 30 7 28 20
African American 9 1 12 4
Hispanic 7 3 8 9
Asian 20 3 1 1
Smokers (n) 5 3 5 4
Data are expressed as group mean (SD). AB able-bodied, SCI spinal cord injury, Normal: HDL-C >40 mg/dl; Low: HDL-C ≤40 mg/dl; BMI body mass index, AIS
American Spinal Injury Association Impairment Scale, DOI duration of injury. P-values represent significant group main effects. Significant comparisons from
post-hoc analyses: 1AB –Normal v. SCI-Low = p < 0.05
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characterized by obesity [14] and insulin resistance
[12, 15–18], and in whom the risk for cardiovascular-
related morbidity and mortality is elevated compared to
the general population [21–23]. Our findings for athero-
genic lipid patterns were then related to TG concentra-
tions and degrees of insulin resistance, an underlying
component of the metabolic syndrome that is becoming
increasingly common across the lifespan in the general
population. In this study, individuals with SCI and normal
HDL-C (i.e., ≥40 mg/dl), who were not statistically differ-
ent for body composition, FPI, TG or LP-IR from the AB-
Normal group, had negligible differences in the lipopro-
tein particle profile (i.e., VLDL, LDL, TG, TC), except for
HDL-C and the total number of HDL-P. However, the re-
duction in HDL-C and HDL-P in the SCI-Normal group
may be speculated to be a consequence of greater degrees
of insulin resistance due to the influence of unfavorable
soft tissue body composition changes that occur with pro-
longed reductions in physical activity, characteristics
which represent the classic determinants of insulin resist-
ance [28]. Thus, it may be speculated that if individuals in
the SCI-Normal group were to continue to gain adiposity,
they would likely progress to an insulin resistant state and
develop a lipoprotein profile comparable to those individ-
uals in the SCI-Low group. The SCI-Low group (i.e.,
HDL-C <40 mg/dl), who were characterized as having an
absolute or statistically significant increase in waist cir-
cumference, waist-to-hip ratio, TG concentrations and
near significant elevations in FPI compared to AB-Normal
and SCI-Normal groups, presented with a composition of
lipid particles that is associated with a heightened athero-
genic risk and greater tendency toward insulin resistance
when characterized by the LP-IR. The SCI-Low and AB-
Low groups were remarkably similar for many of the lipo-
protein subparticles. Thus, those individuals with SCI who
have an increased waist circumference (i.e., abdominal adi-
posity) and HDL-C <40 mg/dl may require a more aggres-
sive level of evaluation and intervention; this may include
the management of TG concentrations even if they are
below the conventional therapeutic cutoff value to initiate
pharmaceutical intervention. These points are especially
relevant when considering that all LDL-C measurements
were consistent across study groups and were well below
therapeutic targets for initiation and management estab-
lished by National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III) criterion [29].
Table 2 Blood and Lipid Profiles by HDL Group
AB-Normal AB-Low SCI-Normal SCI- Low p-value Post-Hoc
Glucose (mmol/l) 4.9 (4.7, 5.1) 5.0 (4.6,5.5) 4.4 (4.1, 4.6) 4.3 (4.0, 4.6) <0.0001 1,2
Insulin (mU/ml) 18.1 (13.2, 22.9) 27.5 (17.8, 37.1) 19.1 (14.3, 23.8) 27.6 (22.0, 33.2) 0.03
Lipids
Triglycerides (mg/dl) 91 (75, 107) 124 (94, 153) 109 (93, 125) 137 (118, 157) <0.001 2
Total Cholesterol (mg/dl) 187 (176, 197) 178 (158, 196) 181 (170, 192) 166 (153, 179) 0.1
LDL-C (mg/dl) 109 (100, 118) 117 (101, 133) 110 (101, 119) 104 (93, 114) NS
HDL-C (mg/dl) 59 (56, 62) 37 (31, 42) 49 (46, 52) 35 (31, 38) <0.0001 1,2,3,4
NMR lipoprotein particle measures
VLDL Particle Number (μmol/l) 53.4 (45.3, 61.7) 61.5 (46.3, 76.8) 56.4 (48.3, 64.6) 71.8 (62.1, 81.6) <0.05 2
Large VLDL (μmol/l) 2.6 (1.4, 3.8) 4.3 (2.6, 7.1) 3.6 (2.4, 4.8) 5.5 (4.0, 6.9) <0.05 2
Small VLDL (μmol/l) 31.8 (26.7, 37.0) 30.2 (16.6, 35.7) 32.9 (27.9, 38.1) 41.2 (35.0, 49.3) <0.05 5
LDL Particle Number (nmol/l) 1088 (989, 1187) 1349 (1166, 1534) 1211 (1112, 1309) 1175 (1056, 1293) 0.08
IDL (nmol/l) 89 (67, 112) 97 (55, 139) 111 (90, 132) 87 (62, 112) NS
Large LDL (nmol/l) 503 (444, 561) 372 (265, 478) 467 (409, 524) 390 (321, 459) 0.06
Small LDL (nmol/l) 504 (421, 587) 887 (735, 1041) 633 (551, 715) 698 (599, 796) <0.0001 2,3
HDL Particle Number (μmol/l) 35.6 (34.2, 37.0) 28.2 (25.6, 30.8) 31.1 (29.7, 32.5) 25.2 (23.5, 27.0) <0.0001 1,2,3,6
Large HDL (μmol/l) 6.6 (5.9, 7.3) 2.1 (0.7, 3.4) 4.6 (3.9, 5.3) 2.4 (1.5, 3.3) <0.0001 1,2,3,4,6
Small HDL (μmol/l) 16.7 (15.3, 18.1) 17.9 (15.2, 20.5) 15.8 (14.4, 17.2) 14.6 (12.9, 16.3) NS
VLDL Particle Size (nm) 45.7 (43.8, 47.7) 49.0 (45.4, 52.6) 47.8 (45.9, 49.7) 48.5 (46.2, 50.8) NS
LDL Particle Size (nm) 20.9 (20.8, 21.1) 20.3 (20.0, 20.5) 20.9 (20.8, 21.1) 20.6 (20.4, 20.8) <0.0001 2,3,4,6
HDL Particle Size (nm) 9.2 (9.1, 9.3) 8.6 (8.4, 8.8) 9.0 (8.9, 9.2) 8.7 (8.6, 8.9) <0.0001 2,3,4,6
Data are expressed as group mean (95 % CI). AB able-bodied, SCI spinal cord injury, Normal: HDL-C >40 mg/dl; Low: HDL-C ≤40 mg/dl; NMR nuclear magnetic
resonance, VLDL very low density lipoprotein, LDL low density lipoprotein, IDL intermediate density lipoprotein, HDL high density lipoprotein. P-values represent
significant group main effects. 1AB-Normal v. SCI-Normal = p < 0.05; 2AB-Normal v. SCI-Low = p < 0.05; 3AB-Normal v. AB-Low= p < 0.05; 4SCI-Normal v. AB-Low= p < 0.05;
5AB-Normal v. SCI-Low = p = 0.06; 6SCI-Normal v. SCI-Low = p < 0.05
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Table 3 Pearson correlations between NMR subclass particle size with FPI by HDL group
AB-Normal AB-Low SCI-Normal SCI-Low
r p value r p value r p value r p value
Particle Size
VLDL 0.27 0.09 - NS 0.30 0.055 0.35 0.057
LDL - NS 0.6 0.09 - NS −0.32 0.09
HDL −0.34 0.03 - NS - NS −0.31 0.09
Particle Subclasses
VLDL
Total - NS −0.30 0.052 0.41 0.02
Large 0.27 0.09 - NS - NS 0.36 0.053
Small - NS - NS - NS 0.33 0.07
LDL
Total - NS - NS - NS 0.44 0.02
Intermediate - NS - NS −0.27 0.08 - NS
Large - NS - NS - NS - NS
Small 0.33 0.055 - NS 0.32 0.04 0.60 0.0001
HDL
Total - NS - NS - NS - NS
Large −0.31 0.053 - NS - NS −0.37 0.05
Small - NS - NS - NS - NS
Correlations between group means for FPI and the respective NMR lipoprotein particle. AB able-bodied, SCI spinal cord injury, Normal: HDL-C >40 mg/dl; Low:
HDL-C ≤40 mg/dl; VLDL very low density lipoprotein, LDL low density lipoprotein, HDL high density lipoprotein
Table 4 Pearson correlations between NMR subclass particle size with TG by HDL Group
AB-Normal AB-Low SCI-Normal SCI-Low
r p value r p value r p value r p value
Particle Size
VLDL 0.46 <0.001 0.64 <0.05 0.49 <0.0001 0.65 <0.0001
LDL −0.27 0.06 - NS −0.50 <0.0001 −0.57 <0.001
HDL −0.39 <0.01 - NS 0.49 <0.001 −0.3 0.08
Particle Subclasses
VLDL
Total 0.75 <0.0001 0.88 <0.0001 0.59 <0.0001 0.56 0.001
Large 0.79 <0.0001 0.86 <0.0001 0.84 <0.0001 0.75 <0.0001
Small 0.37 <0.01 - NS - NS - NS
LDL
Total 0.36 <0.05 0.49 0.07 0.60 <0.0001 0.42 <0.02
Intermediate - NS - NS - NS - NS
Large - NS - NS - NS - NS
Small 0.32 <0.05 - NS 0.70 <0.0001 0.66 0.005
HDL
Total - NS - NS - NS - NS
Large −0.25 0.08 - NS −0.37 0.01 −0.44 0.01
Small 0.26 0.07 - NS - NS 0.39 0.02
Correlations between group means for TG and the respective NMR lipoprotein particle. AB able-bodied, SCI spinal cord injury, Normal: HDL-C >40 mg/dl; Low:
HDL-C ≤40 mg/dl; VLDL very low density lipoprotein, LDL low density lipoprotein, HDL high density lipoprotein
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As has been well appreciated, HDL-C concentrations
are strong predictors for the risk of a cardiovascular
event, even after adjusting for other conventional risk
factors [30, 31]. More specifically, the risk for CAD in-
creases by 3 % in women and 2 % in men for every
1 mg/dl decrease in HDL-C [32]. By this calculation of
risk solely derived from HDL-C values, our SCI-Normal
and SCI-Low groups have a minimum 20 % and 48 %
increased risk for CAD, respectively, relative to our AB-
Normal cohort. While our finding of depressed HDL-C
tends to support the observed relative increase in
cardiovascular-related morbidity and mortality rates in
the SCI population [21–23], recent evidence from the
Multi-ethic Study of Atherosclerosis (MESA) suggests
that risk remediation had more to do with increasing the
number of HDL-P than merely raising the HDL-C [3]. A
reduction in the total number of HDL-P has predicted
incident cardiac events in large and multi-national inter-
vention trials [4, 33]. Increased numbers of HDL-P may
reflect a greater capacity for reverse cholesterol trans-
port to the liver for cholesterol disposal from the periph-
ery [34] and possess a greater anti-oxidant capacity
beyond that attributed to HDL-C alone [33], and thus be
associated with a cardioprotective profile. Compared to
the AB-Normal group, both the SCI-Low and SCI-
Normal cohorts had markedly reduced numbers of Total
and Large HDL-P, a lipid pattern which is compatible
with heightened vascular risk.
The National Health and Nutrition Examination Survey
(NHANES) revealed that increased sitting time was sig-
nificantly associated with adverse cardiometabolic risk fac-
tors [35]; those individuals who had a self-reported time
sitting for more than 6 hours per day, were more likely to
have adverse FPI, HDL-C concentrations, and HOMA-IR
and HOMA % B scores [36], and, thus, a greater inferred
CVD risk. As a consequence of paralysis and the inability
to assume upright standing and ambulation, time spent
sitting in a wheelchair in those with SCI has been self-
reported to be, on average, 9.2 hours per day [37], and, in
the anecdotal experience of the authors, it is not uncom-
mon for these individuals to spend in excess of 12–15
hours sitting in their wheelchair on a daily basis, with the
remaining balance of non-sleeping time during the day
spent in a seated or non-weight bearing position (i.e.,
seated on surface other than wheelchair). Our SCI cohort
has lived with their immobilizing injury from 6 months to
47 years. Thus, the increased risk for CVD in the SCI
population appears to be, in part, a consequence of
chronic immobility, prolonged sitting and restricted phys-
ical activity, abnormal body composition and an associated
greater prevalence of perturbations in carbohydrate and
lipid metabolism [12, 14–18, 20].
Insulin resistance at the level of the adipocyte results
in a state of relatively increased hydrolysis of triglycer-
ides with the release of fatty acids into the circulation,
stimulating the hepatic formation and secretion of VLDL
[38] resulting in hypertriglyceridemia and a proathero-
genic state [39]. According to presently accepted dogma,
elevated circulating TG, mainly in the form of VLDL,
deplete LDL-C and HDL-C by a two-step process: TG
replaces cholesterol ester one-to-one in the lipid core
through the action of cholesterol ester transfer protein,
and then these incorporated TG in the lipid particles are
hydrolyzed by the action of lipases, which results in
Fig 1 Lipoprotein Profile Insulin Resistance Score (LP-IR) across HDL groups. Data are presented as group mean (i.e., solid vertical bar) and individual
subject score (i.e., small mark). *p < 0.01; **p < 0.0001. Abbreviations: AB = able-bodied; SCI = spinal cord injury; Normal: HDL-C >40 mg/dl;
Low: HDL-C ≤40 mg/dl
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cholesterol-depleted particles of reduced size across all
subclasses [24, 40, 41]. The smaller LDL-P have the po-
tential to migrate through the vessel wall, become more
highly oxidized, and then more readily adhere to the
subendothelial space; this sequence of events promotes
ongoing atherogenic plaque formation. Insulin resistance
may be postulated to have a direct adverse effect on the
lipid subclasses and number of VLDL, LDL and HDL
lipoprotein particles [25]; this concept was reinforced by
the LP-IR score, which is a composite index of several of
these particles, and was most adverse in the SCI-Low
group.
Analogous to the prior discussion on HDL-P, the num-
ber and size of LDL-P are stronger predictors for CVD
than relying exclusively upon LDL-C alone [42, 43]. As
previously discussed, LDL-P possess a highly variable
cholesterol content [40] with TG levels playing a deter-
mining role in species differentiation [24]. NCEP ATP III
guidelines categorize LDL cholesterol levels for optimal,
above optimal, borderline-high, and high/very high risk
[29]. Similarly, the Framingham Offspring Study catego-
rizes number of total LDL-P for optimal (<1100 nmol/l),
above optimal (1100–1400 nmol/l), borderline-high
(1400–1800 nmol/l), and high/very high (>1800 nmol/l)
risk [44]. Employing this approach, the preponderance
of our SCI cohort has a number of total LDL-P that fell
within the near to or “above optimal” range and, as such,
may certainly be candidates for appropriate intervention
strategies if the lipid particle number is taken into consid-
eration, but would not have been deemed to be suitable
candidates for lipid-lowering therapy based on conven-
tional approaches to care. Therefore, alternate strategies
must be considered for the clinical management of the
appreciated heightened risk of sub-clinical burden of
vascular disease in this highly sedentary population.
In the general population, a clear association has been
demonstrated between HDL-C and LDL-C [45, 46].
When HDL-C exceeds 50 mg/dl, Large LDL-P species
predominate, but with values of HDL-C below 40 mg/dl,
a striking increase in Small LDL-P occurs, associated
with a precipitous decline in Large LDL-P [46]. As a re-
sult, there is a large disparity between LDL-C and LDL-
P in persons with low HDL-C values, as was found in
our SCI cohort. The marked reduction observed in the
general population in large HDL-P at low HDL-C was
also found to be evident to an even greater extent in our
SCI-Low group. Thus, persons with SCI and low HDL-
C, a designation which represents a far larger portion of
the SCI than the general population, have an increased
atherogenic risk not only on the basis of a depressed
HDL-C, but also because of the adverse LDL particle
profile, which may not be recognized to be a of concern
if only the LDL-C is available when therapeutic decisions
are being formulated.
In the literature, exercise and/or pharmacological in-
terventions have been performed with success in the
general population, and these life modifications have
been performed to a far more limited extent in those
with SCI. In persons with SCI, formally structured [47]
and routine exercise programs [48], or the combination
of exercise and diet programs [49] have demonstrated
efficacy at modifying adverse lipid concentrations.
Achieving a high-level of physical activity and perform-
ance serves to improve HDL-C compared to being sed-
entary in persons with SCI, but the restrictive effects of
paralysis on physical activity favors a reduction of HDL-
C compared to the general able-bodied population [50].
A randomized, double-blind, placebo controlled clinical
trial with Niaspan was effective at increasing HDL-C by
approximately 25 % in persons with tetraplegia, but, un-
fortunately, lipid particle number and size were not per-
formed in this study [51]. Because of the limitations of
physical activity in the SCI population, interventions
with appropriate lipid-lowering agents may hold greater
promise to promote vascular health. The LP-IR score
displayed a vast distribution across the spectrum from
insulin sensitivity to resistance, irrespective of HDL-C,
possibly due in large measure to normal genetic variation
of any population sample. The determinants of insulin
resistance—that is, adverse soft tissue body composition
and physical inactivity—are modifiable by lifestyle
changes; thus, by increasing insulin sensitivity, the dyslip-
idemia may be anticipated to be mitigated, which ultim-
ately would reduce atherogenesis and cardiovascular
events. In individuals with non-modifiable limitations to
activity, the ability to improve the determinants of insulin
resistance by modification of lifestyle alone is severely
compromised, leading to the appreciation that pharmaco-
logical intervention remains the only viable course of
action to reduce CVD risk.
Our study design had limitations that precluded the
ability to further differentiate risk or stratify outcomes in
a descriptive manner, or to better identify the contribut-
ing factors for insulin resistance. Although persons with
SCI have lower extremity paralysis that limits the inten-
sity of exercise, individuals, especially those with lower
cord lesions, may engage in varying degrees of physical
activity as part of community mobility and leisure activ-
ity. However, the level of physical activity of our subjects
with SCI was not captured, but the average intensity of
activity may generally be assumed to be low because
there were no SCI subjects capable of ambulation. Diet-
ary habits and food choice is appreciated to play an inte-
gral role in determining the lipoprotein profile, but food
diaries or dietary recalls were not obtained. Direct body
composition measurements were not included in our
analysis, which prevented us from determining if rela-
tionship(s) existed between total body or regional fat
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tissue compartments or lean tissue mass and lipoprotein
particle number or size. Our subjects with SCI were
community-dwelling individuals who frequented the two
study sites, where they receive routine outpatient care
or, on occasion, participated in clinical trials. Therefore,
the results of the current report may be biased and may
not reflect the larger SCI population, who are home-
bound or do not routinely present themselves at medical
facilities, or those who have little interest in participating
in clinical investigation. Although there is confidence
that our findings characterize the general SCI cohort, a
larger, more diverse and comprehensive sampling from
several geographical locations should be performed to
confirm these results.
Conclusions
The effects of restricted physical activity and adverse
body composition changes in individuals with SCI had
the most profound association to declines in HDL lipo-
protein subclasses compared to the able-bodied groups.
Once HDL-C concentrations fell below 40 mg/dl and as-
sociated with an increased waist circumference, a rela-
tively elevated TG (compared to the other subgroups)
and an underlying sub-clinical state of insulin resistance
resulted; these factors were closely related to a more
atherogenic profile of lipoprotein particles, despite most
individuals with SCI having LDL-C values that failed to
be in the treatment range to consider initiating lipid-
lowering therapy. Therapeutic and lifestyle interventions
to reduce CVD-related risk in the SCI cohort should be
designed to reduce insulin resistance, reduce abdominal
adiposity and, if possible, modestly increase the level of
activity; more appropriate (i.e., lower) therapeutic
thresholds may be considered for serum TG concentra-
tions to improve the dyslipidemia associated with immo-
bilizing disorders. Thus, the utilization of NMR
spectroscopy to determine lipid particle number and size
in persons who are extremely sedentary will provide
clinical insight to more accurately predict the risk of
CVD morbidity and mortality, and thus to prevent the
underestimation of risk. NMR spectroscopy may also be
utilized to determine the efficacy of clinical interventions
which are employed to treat dyslipidemias in popula-
tions that are immobilized by neurological conditions or
disease, spinal abnormalities, rheumatological ailments,
and lower limb amputation in our effort to modify risk
for CVD.
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